A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnett, A K, Russell, N H, Hills, R K, Kell, J, Nielsen, O J, Dennis, M, Cahalin, P, Pocock, C, Ali, S, Burns, S, Freeman, S, Milligan, D, Clark, R E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292678/
https://www.ncbi.nlm.nih.gov/pubmed/27624670
http://dx.doi.org/10.1038/leu.2016.225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292678/
https://www.ncbi.nlm.nih.gov/pubmed/27624670
http://dx.doi.org/10.1038/leu.2016.225

Ejemplares similares